Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 1

Conditions

Leukemia, Myeloid, Acute 15Leukemia 7Recurrence 5Solid Tumors 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Erythroblastic, Acute 1Hematologic Neoplasms 1Aortic aneurysm, familial thoracic 4 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × quizartinib × Clear all
NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Daiichi Sankyo

Phase 1/2 Active not recruiting
65 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03552029 2022-05-20

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Daiichi Sankyo

Phase 1 Terminated
10 enrolled 10 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00462761 2020-05-11

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Daiichi Sankyo

Phase 1 Completed
76 enrolled 12 charts
MyeloidOther hematologic neoplasm

Aortic aneurysm, familial thoracic 4, Leukemia, Erythroblastic, Acute, Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT01565668 2019-12-27

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Daiichi Sankyo

Phase 2 Completed
76 enrolled 17 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00989261 2019-12-11

ACE

Daiichi Sankyo

Phase 2 Completed
333 enrolled 23 charts
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡